Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea Biotech, Berkshire Medical Center Collaborate on Prostate, Breast Cancer Biomarker Identification

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies today announced a research and collaboration agreement with Berkshire Medical Center aimed at prostate cancer and breast cancer biomarker identification.

As part of the deal, Berkshire — the primary affiliate of Berkshire Health Systems — will provide Nuclea with samples of serum and tumor tissue for the identification of biomarkers for cancer diagnostics, with patient consent. Pittsfield, Mass.-based Nuclea develops genetic, protein, and antibody biomarkers and diagnostic assays to help determine which therapeutics may be most appropriate for individual patients.

Last month, it said it raised $4.2 million of a targeted $5 million in a Series D round.

Financial and other terms of the today's deal were not disclosed.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.